Phase I/Investigational Therapeutics Program

The Phase I/Investigational Therapeutics Program is a multidisciplinary scientific group designed to develop new methods for the treatment of cancer. The program includes a team of medical oncologists, nurses, research scientists, data coordinators and social workers who have extensive experience in providing novel therapeutic strategies.

Through this program, patients and physicians have access to the newest and most promising anti-cancer treatments supported by the National Cancer Institute, pharmaceutical companies and CINJ. Patients with a variety of malignancies are typically eligible to receive these treatments. The team meets weekly to discuss current and pending clinical trials and reviews all patients on Phase I clinical trials.

Clinical Trials:

Staff of this Program:

Janice Mehnert, MD, Interim Director, Phase I and Developmental Therapeutics Program, and Medical Oncologist
Joseph Aisner, MD, Medical Oncologist 
Nancy Chan, MD, Medical Oncologist
Darlene Gibbon, MD, Chief, Gynecologic Oncology 
Rebecca Moss, MD, Medical Oncologist 
Mark Stein, MD, Medical Oncologist
Joan Quagliata, RN, Primary Treatment Nurse
Heather Camisa, RN, Research Nurse
Marjorie LaRosiliere, RN, Research Nurse
Pamela Scott, RN, Research Nurse
Cecilila Thomas, RN, Research Nurse
Barbara Hale, MSW, Social Worker
Kiomi Harris-Addo, Clinical Research Review Specialist
Shari Adams, Clinical Research Review Specialist
Samantha Williams, Clinical Research Review Specialist
Anna Wong, CRC, Clinical Research Review Specialist